GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acino Holding AG (FRA:S3H) » Definitions » ROE %

Acino Holding AG (FRA:S3H) ROE % : -5.25% (As of Dec. 2013)


View and export this data going back to . Start your Free Trial

What is Acino Holding AG ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Acino Holding AG's annualized net income for the quarter that ended in Dec. 2013 was €-14.5 Mil. Acino Holding AG's average Total Stockholders Equity over the quarter that ended in Dec. 2013 was €276.3 Mil. Therefore, Acino Holding AG's annualized ROE % for the quarter that ended in Dec. 2013 was -5.25%.

The historical rank and industry rank for Acino Holding AG's ROE % or its related term are showing as below:

FRA:S3H' s ROE % Range Over the Past 10 Years
Min: -5.29   Med: 4.46   Max: 13.77
Current: -5.29

During the past 11 years, Acino Holding AG's highest ROE % was 13.77%. The lowest was -5.29%. And the median was 4.46%.

FRA:S3H's ROE % is not ranked
in the Drug Manufacturers industry.
Industry Median: 4.25 vs FRA:S3H: -5.29

Acino Holding AG ROE % Historical Data

The historical data trend for Acino Holding AG's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acino Holding AG ROE % Chart

Acino Holding AG Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.94 1.78 2.25 2.81 -5.25

Acino Holding AG Semi-Annual Data
Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 13.94 1.78 2.25 2.81 -5.25

Competitive Comparison of Acino Holding AG's ROE %

For the Drug Manufacturers - General subindustry, Acino Holding AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acino Holding AG's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's ROE % distribution charts can be found below:

* The bar in red indicates where Acino Holding AG's ROE % falls into.



Acino Holding AG ROE % Calculation

Acino Holding AG's annualized ROE % for the fiscal year that ended in Dec. 2013 is calculated as

ROE %=Net Income (A: Dec. 2013 )/( (Total Stockholders Equity (A: Dec. 2012 )+Total Stockholders Equity (A: Dec. 2013 ))/ count )
=-14.514/( (279.462+273.071)/ 2 )
=-14.514/276.2665
=-5.25 %

Acino Holding AG's annualized ROE % for the quarter that ended in Dec. 2013 is calculated as

ROE %=Net Income (Q: Dec. 2013 )/( (Total Stockholders Equity (Q: Dec. 2012 )+Total Stockholders Equity (Q: Dec. 2013 ))/ count )
=-14.514/( (279.462+273.071)/ 2 )
=-14.514/276.2665
=-5.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (Dec. 2013) net income data. ROE % is displayed in the 30-year financial page.


Acino Holding AG  (FRA:S3H) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2013 )
=Net Income/Total Stockholders Equity
=-14.514/276.2665
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-14.514 / 262.442)*(262.442 / 481.933)*(481.933 / 276.2665)
=Net Margin %*Asset Turnover*Equity Multiplier
=-5.53 %*0.5446*1.7444
=ROA %*Equity Multiplier
=-3.01 %*1.7444
=-5.25 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2013 )
=Net Income/Total Stockholders Equity
=-14.514/276.2665
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-14.514 / -18.698) * (-18.698 / -14.975) * (-14.975 / 262.442) * (262.442 / 481.933) * (481.933 / 276.2665)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7762 * 1.2486 * -5.71 % * 0.5446 * 1.7444
=-5.25 %

Note: The net income data used here is one times the annual (Dec. 2013) net income data. The Revenue data used here is one times the annual (Dec. 2013) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Acino Holding AG ROE % Related Terms

Thank you for viewing the detailed overview of Acino Holding AG's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acino Holding AG (FRA:S3H) Business Description

Traded in Other Exchanges
N/A
Address
Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.

Acino Holding AG (FRA:S3H) Headlines

No Headlines